Dossier
PCSK9
Coverage of PCSK9 in the Nexus archive.
- FDA nod to Merck’s cholesterol pill opens a new frontier in cardiovascular care
The FDA approved Merck’s Lipfendra, the first non-injectable pill targeting PCSK9 to significantly reduce LDL cholesterol in patients not adequately controlled by statins. Clinical trials showed over 55% LDL reduction, and the drug was reviewed under the FDA's fast-track program.
- FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients
The FDA approved Merck's Lipfendra, the first non-injectable pill to block PCSK9 and significantly reduce LDL cholesterol in high-risk patients. Clinical trials showed over 55% LDL reduction in six months, with minimal side effects, positioning it as an alternative to costly injectable PCSK9 inhibitors previously available from Amgen and others.